表紙
市場調査レポート

慢性リンパ球性白血病(CLL):パイプライン製品の分析

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 192526
出版日 ページ情報 英文 782 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
慢性リンパ球性白血病(CLL):パイプライン製品の分析 Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016
出版日: 2016年05月31日 ページ情報: 英文 782 Pages
概要

慢性リンパ球性白血病(CLL)は、骨髄の(リンパ球と呼ばれる)白血球で始まる癌の一種で、その後、血液を侵します。異常なあざ(血小板が少ない場合)、発熱、感染症の再発、食欲不振または早期の満腹感、体重減少などの症状が見られます。治療は、外科手術、放射線療法、化学療法、またはいくつかを併用して行われます。

当レポートでは、慢性リンパ球性白血病(CLL)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

慢性リンパ球性白血病(CLL)の概要

治療薬の開発

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

治療薬の評価

薬剤のプロファイル

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7977IDB

Summary

Global Markets Direct's, 'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016', provides an overview of the Chronic Lymphocytic Leukemia (CLL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL)
  • The report reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects
  • The report assesses Chronic Lymphocytic Leukemia (CLL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Chronic Lymphocytic Leukemia (CLL) Overview
  • Therapeutics Development
  • Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies
  • Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance
  • Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies
  • Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes
  • Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development
  • Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment
  • Drug Profiles
  • Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects
  • Chronic Lymphocytic Leukemia (CLL) - Discontinued Products
  • Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2016
  • Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Altor BioScience Corporation, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amgen Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Baliopharm AG, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bayer AG, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by BeiGene, Ltd., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biogen, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by BioInvent International AB, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionovis SA, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellectis S.A., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celltrion, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Clonz Biotech Private Limited, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eli Lilly and Company, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Emergent BioSolutions Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by GeneaMed Ltd., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genentech, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genor BioPharma Co., Ltd., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hybrigenics S.A., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Igenica Biotherapeutics, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Inflection Biosciences Limited, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma S.A., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innovent Biologics, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Johnson & Johnson, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kancera AB, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kite Pharma, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lead Discovery Center GmbH, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by MEI Pharma, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by MENTRIK Biotech, LLC, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck & Co., Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck KGaA, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Mirna Therapeutics, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by NantKwest, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Panacea Biotec Limited, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by PEP-Therapy SAS, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pharmacyclics, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Plexxikon Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Polyphor Ltd., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Respiratorius AB, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Revitope Oncology, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sandoz International GmbH, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Selvita S.A., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Simcere Pharmaceutical Group, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sorrento Therapeutics, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Supratek Pharma Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Targazyme, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Theravectys SA, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tolero Pharmaceuticals, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Trillium Therapeutics Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Unum Therapeutics, Inc., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Viralytics Ltd., H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Zymeworks Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..2), H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..3), H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..4), H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..5), H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..6), H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..7), H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..8), H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..9), H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..10), H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..11), H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2016
  • Chronic Lymphocytic Leukemia (CLL) - Discontinued Products (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2016
  • Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top